326 related articles for article (PubMed ID: 31820586)
1. Peptidylarginine Deiminase Autoimmunity and the Development of Anti-Citrullinated Protein Antibody in Rheumatoid Arthritis: The Hapten-Carrier Model.
Auger I; Balandraud N; Massy E; Hemon MF; Peen E; Arnoux F; Mariot C; Martin M; Lafforgue P; Busnel JM; Roudier J
Arthritis Rheumatol; 2020 Jun; 72(6):903-911. PubMed ID: 31820586
[TBL] [Abstract][Full Text] [Related]
2. Peptidyl arginine deiminase immunization induces anticitrullinated protein antibodies in mice with particular MHC types.
Arnoux F; Mariot C; Peen E; Lambert NC; Balandraud N; Roudier J; Auger I
Proc Natl Acad Sci U S A; 2017 Nov; 114(47):E10169-E10177. PubMed ID: 29109281
[TBL] [Abstract][Full Text] [Related]
3. How RA Associated HLA-DR Molecules Contribute to the Development of Antibodies to Citrullinated Proteins: The Hapten Carrier Model.
Roudier J; Balandraud N; Auger I
Front Immunol; 2022; 13():930112. PubMed ID: 35774784
[TBL] [Abstract][Full Text] [Related]
4. Do RA associated HLA-DR molecules bind citrullinated peptides or peptides from PAD4 to help the development of RA specific antibodies to citrullinated proteins?
Balandraud N; Auger I; Roudier J
J Autoimmun; 2021 Jan; 116():102542. PubMed ID: 32928608
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of anti-peptidylarginine deiminase type 4 antibodies in rheumatoid arthritis and unaffected first-degree relatives in indigenous North American Populations.
Ferucci ED; Darrah E; Smolik I; Choromanski TL; Robinson DB; Newkirk MM; Fritzler MJ; Rosen A; El-Gabalawy HS
J Rheumatol; 2013 Sep; 40(9):1523-8. PubMed ID: 23908443
[TBL] [Abstract][Full Text] [Related]
6. Clinical and immunological aspects of anti-peptidylarginine deiminase type 4 (anti-PAD4) autoantibodies in rheumatoid arthritis.
Reyes-Castillo Z; Muñoz-Valle JF; Llamas-Covarrubias MA
Autoimmun Rev; 2018 Feb; 17(2):94-102. PubMed ID: 29196243
[TBL] [Abstract][Full Text] [Related]
7. Citrulline Not a Major Determinant in the Recognition of Peptidylarginine Deiminase 2 and 4 by Autoantibodies in Rheumatoid Arthritis.
Darrah E; Davis RL; Curran AM; Naik P; Chen R; Na CH; Giles JT; Andrade F
Arthritis Rheumatol; 2020 Sep; 72(9):1476-1482. PubMed ID: 32255561
[TBL] [Abstract][Full Text] [Related]
8. Relative efficiencies of peptidylarginine deiminase 2 and 4 in generating target sites for anti-citrullinated protein antibodies in fibrinogen, alpha-enolase and histone H3.
Damgaard D; Bawadekar M; Senolt L; Stensballe A; Shelef MA; Nielsen CH
PLoS One; 2018; 13(8):e0203214. PubMed ID: 30161253
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies to Peptidylarginine Deiminase 2 Are Associated With Less Severe Disease in Rheumatoid Arthritis.
Darrah E; Giles JT; Davis RL; Naik P; Wang H; Konig MF; Cappelli LC; Bingham CO; Danoff SK; Andrade F
Front Immunol; 2018; 9():2696. PubMed ID: 30515171
[No Abstract] [Full Text] [Related]
10. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
Li B; Li P; Bi L
Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of autoantibodies targeting peptidylarginine deiminase type 4, mutated citrullinated vimentin and cyclic citrullinated peptides in rheumatoid arthritis: associations with cytokine profiles, clinical and genetic features.
Reyes-Castillo Z; Palafox-Sánchez CA; Parra-Rojas I; Martínez-Bonilla GE; del Toro-Arreola S; Ramírez-Dueñas MG; Ocampo-Bermudes G; Muñoz-Valle JF
Clin Exp Immunol; 2015 Nov; 182(2):119-31. PubMed ID: 26149185
[TBL] [Abstract][Full Text] [Related]
12. Differential ACPA Binding to Nuclear Antigens Reveals a PAD-Independent Pathway and a Distinct Subset of Acetylation Cross-Reactive Autoantibodies in Rheumatoid Arthritis.
Lloyd KA; Wigerblad G; Sahlström P; Garimella MG; Chemin K; Steen J; Titcombe PJ; Marklein B; Zhou D; Stålesen R; Ossipova E; Lundqvist C; Ekwall O; Rönnelid J; Mueller DL; Karlsson MCI; Kaplan MJ; Skriner K; Klareskog L; Wermeling F; Malmström V; Grönwall C
Front Immunol; 2018; 9():3033. PubMed ID: 30662440
[TBL] [Abstract][Full Text] [Related]
13. Affinity maturation shapes the function of agonistic antibodies to peptidylarginine deiminase type 4 in rheumatoid arthritis.
Shi J; Darrah E; Sims GP; Mustelin T; Sampson K; Konig MF; Bingham CO; Rosen A; Andrade F
Ann Rheum Dis; 2018 Jan; 77(1):141-148. PubMed ID: 29070531
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of soluble peptidylarginine deiminase 4 (PAD4) and anti-PAD4 antibodies in autoimmune diseases.
Umeda N; Matsumoto I; Kawaguchi H; Kurashima Y; Kondo Y; Tsuboi H; Ogishima H; Suzuki T; Kagami Y; Sakyu T; Ishigami A; Maruyama N; Sumida T
Clin Rheumatol; 2016 May; 35(5):1181-8. PubMed ID: 26415740
[TBL] [Abstract][Full Text] [Related]
15. Macrophage extracellular traps require peptidylarginine deiminase 2 and 4 and are a source of citrullinated antigens bound by rheumatoid arthritis autoantibodies.
Bashar SJ; Holmes CL; Shelef MA
Front Immunol; 2024; 15():1167362. PubMed ID: 38476240
[TBL] [Abstract][Full Text] [Related]
16. High-Titer Rheumatoid Arthritis Antibodies Preferentially Bind Fibrinogen Citrullinated by Peptidylarginine Deiminase 4.
Blachère NE; Parveen S; Frank MO; Dill BD; Molina H; Orange DE
Arthritis Rheumatol; 2017 May; 69(5):986-995. PubMed ID: 28029744
[TBL] [Abstract][Full Text] [Related]
17. Protein Citrullination by Peptidyl Arginine Deiminase/Arginine Deiminase Homologs in Members of the Human Microbiota and Its Recognition by Anti-Citrullinated Protein Antibodies.
Pérez-Pérez ME; Nieto-Torres E; Bollain-Y-Goytia JJ; Delgadillo-Ruíz L
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791230
[TBL] [Abstract][Full Text] [Related]
18. Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays.
Poulsen TBG; Damgaard D; Jørgensen MM; Senolt L; Blackburn JM; Nielsen CH; Stensballe A
Sci Rep; 2021 Aug; 11(1):17300. PubMed ID: 34453079
[TBL] [Abstract][Full Text] [Related]
19. PAD enzymes in rheumatoid arthritis: pathogenic effectors and autoimmune targets.
Curran AM; Naik P; Giles JT; Darrah E
Nat Rev Rheumatol; 2020 Jun; 16(6):301-315. PubMed ID: 32341463
[TBL] [Abstract][Full Text] [Related]
20. Anti-peptidylarginine deiminase-4 antibodies at mucosal sites can activate peptidylarginine deiminase-4 enzyme activity in rheumatoid arthritis.
Demoruelle MK; Wang H; Davis RL; Visser A; Hoang J; Norris JM; Holers VM; Deane KD; Darrah E
Arthritis Res Ther; 2021 Jun; 23(1):163. PubMed ID: 34092252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
